Option Care Health (NASDAQ:OPCH) Given Market Outperform Rating at Citizens Jmp

Citizens Jmp reaffirmed their market outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a research report released on Tuesday morning,Benzinga reports. Citizens Jmp currently has a $38.00 price objective on the stock, up from their previous price objective of $36.00.

Other research analysts also recently issued reports about the stock. Stephens raised shares of Option Care Health to a “strong-buy” rating in a research report on Thursday, December 11th. Wall Street Zen raised shares of Option Care Health from a “hold” rating to a “buy” rating in a research note on Saturday. JMP Securities set a $36.00 price target on shares of Option Care Health in a research note on Friday, October 31st. TD Cowen lowered their price objective on shares of Option Care Health from $30.00 to $27.00 and set a “hold” rating for the company in a report on Monday, November 3rd. Finally, Barrington Research reiterated an “outperform” rating and set a $38.00 target price on shares of Option Care Health in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.17.

Option Care Health Price Performance

OPCH opened at $34.75 on Tuesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.05 and a current ratio of 1.56. The stock has a market capitalization of $5.52 billion, a PE ratio of 27.58, a price-to-earnings-growth ratio of 2.00 and a beta of 0.80. The stock’s 50 day moving average price is $30.98 and its 200-day moving average price is $29.42. Option Care Health has a 52-week low of $24.24 and a 52-week high of $35.53.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 38,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was acquired at an average price of $25.98 per share, with a total value of $987,240.00. Following the completion of the purchase, the director owned 413,390 shares of the company’s stock, valued at approximately $10,739,872.20. This trade represents a 10.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. USA Financial Formulas purchased a new position in Option Care Health during the second quarter valued at $26,000. Cornerstone Planning Group LLC increased its holdings in shares of Option Care Health by 7,621.4% during the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock valued at $30,000 after acquiring an additional 1,067 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Option Care Health in the 3rd quarter worth about $35,000. McIlrath & Eck LLC purchased a new position in shares of Option Care Health in the 2nd quarter worth about $37,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Option Care Health in the 3rd quarter worth about $38,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

More Option Care Health News

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: Company-guided EPS above consensus for FY‑2025 and Q4 2025 (FY‑2025 EPS 1.720–1.760 vs. consensus 1.640; Q4 EPS 0.460–0.490 vs. consensus 0.440), which supports higher valuation expectations. Preliminary Results & Guidance
• Positive Sentiment: Morgan Stanley raised its price target to $38 and moved to an “overweight” rating, signaling buy-side momentum and implying further upside from current levels. Benzinga: Morgan Stanley Raise
• Positive Sentiment: Citizens JMP reaffirmed a “market outperform” rating and raised its target to $38 (from $36), echoing the bullish analyst view and providing independent validation of upside. TickerReport: Citizens JMP
• Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference; the transcript is now available for investors seeking detail on strategy, margin drivers, and capital allocation. Insights could influence longer-term sentiment but are informational in the near term. JPM Conference Transcript
• Neutral Sentiment: Reported short‑interest figures appear inconsistent (zeros/NaN), so there’s no clear short‑squeeze signal from the published data — treat that data point cautiously.
• Negative Sentiment: FY‑2026 revenue guidance of $5.8–6.0B is below the consensus cited (~$6.1B), which could cap upside if investors focus on top‑line growth vs. EPS beats. Preliminary Results & Guidance

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.